Astrazeneca Ab

Astra Zeneca U.k. Limited

Fisons Ltd.

Astra Pharmaceuticals Limited

Mark Furber

David K Donald

Martin E Cooper

David R Cheshire

Philip Vellacott Thorne

Matthew Wd Perry

Lilian Alcaraz

Michael P Mortimore

Richard P Harrison

Nicholas P Tomkinsson

Andrew Cooke

Timothy Jon Luker

Paul Andrew Willis

Austen Pimm

Peter Cage

Christopher Luckhurst

Matthew W D Perry

Premji Meghani

Brian Springthorpe

Hitesh Jayantilal Sanganee

David N Hardern

Aaron Rigby

Mark Purdie

Moya Caffrey

Elizabeth Kinchin

Linda Anne Stein

Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).

Piperidines as chemokine modulators (CCR)

The present invention provides compounds of formula (I) in which n, y, X, X, A, B, R, R, R, Rand Rare as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds 010

The invention provides compounds of formula (I): wherein: X is CH, O, S(O)or NR; Y is a bond, CH, NR, CHNH, CHNHC(O), CH(OH), CH(NHCOR), CH(NHSOR), CHO or CHS; Z is C(O), or when Y is a bond Z can also be S(O); Ris optionally substituted aryl, optionally substituted heterocyclyl or Ccycloalkyl fused to a benzene ring; and R, R, R, R, R, Rand R, R, R, R, R, Rand Rare as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

Chemical compounds

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I). 

Adamantane derivatives

The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Treatment of skin disorders using thieno[2,3-D]pyrimidinediones

The invention provides compounds of general formula (I) in which m, A, Rand Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

Admantane derivatives

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I).

Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions

The invention provides pharmaceutically useful thieno&lsqb;2,3-d&rsqb;pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Thieno&lsqb;2,3-d&rsqb; pyrimidinediones, their preparation and use in therapy

Thieno&lsqb;2,3-d&rsqb;pyrimidine diones and their use in the treatment of reversible obstructive airways diseases

Pyrrolo&lsqb;3,4-d&rsqb;pyrimidinone derivatives and their use as medicaments

Process for preparing 5-substituted pyrrolo &lsqb;3,4-d&rsqb; pyrimidine-2-4-diones of formula (I)

Pyrrolo(3,4-d)pyrimidinone derivatives and their use as medicaments

Compounds

Growing community of inventors

Loughborough, United Kingdom

Mark Furber